Search Results - "Yue, Huibin"

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2 by Abraham, Prema, Yue, Huibin, Wilson, Laura

“…Purpose To evaluate efficacy and safety of quarterly (and then monthly) ranibizumab during the 2-year P hase IIIb, multicenter, randomized, double-masked, sham…”
Get full text

Vemurafenib in patients with BRAFV600E -positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial by Brose, Marcia S, Dr, Cabanillas, Maria E, MD, Cohen, Ezra E W, Prof, Wirth, Lori J, MD, Riehl, Todd, PharmD, Yue, Huibin, PhD, Sherman, Steven I, Prof, Sherman, Eric J, MD

“…Summary Background About half of patients with papillary thyroid cancer have tumours with activating BRAFV600E mutations. Vemurafenib, an oncogenic BRAF kinase…”
Get full text

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1 by Regillo, Carl D, Brown, David M, Abraham, Prema, Yue, Huibin, Ianchulev, Tsontcho, Schneider, Susan, Shams, Naveed

“…Purpose To evaluate the efficacy and safety of ranibizumab administered monthly for three months and then quarterly in patients with subfoveal choroidal…”
Get full text

Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease by McCusker, Margaret, Basset-Seguin, Nicole, Dummer, Reinhard, Lewis, Karl, Schadendorf, Dirk, Sekulic, Aleksandar, Hou, Jeannie, Wang, Lisa, Yue, Huibin, Hauschild, Axel

“…Abstract Purpose This review provides a description of the epidemiology and survival outcomes for cases with metastatic basal cell carcinoma (mBCC) based on…”
Get full text

The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time by Stone, John H., McDowell, P. Jane, Jayne, David R.W., Merkel, Peter A., Robson, Joanna, Patel, Naomi J., Zhang, Yuqing, Yue, Huibin, Bekker, Pirow, Heaney, Liam G.

“…Glucocorticoids (GCs) have been the cornerstone of treating dozens of inflammatory conditions for more than seven decades. GC toxicity is ubiquitous in both…”
Get full text

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC by Sekulic, Aleksandar, MD, Migden, Michael R., MD, Lewis, Karl, MD, Hainsworth, John D., MD, Solomon, James A., MD, PhD, Yoo, Simon, MD, Arron, Sarah T., MD, PhD, Friedlander, Philip A., MD, PhD, Marmur, Ellen, MD, Rudin, Charles M., MD, PhD, Chang, Anne Lynn S., MD, Dirix, Luc, MD, PhD, Hou, Jeannie, MD, Yue, Huibin, PhD, Hauschild, Axel, MD

“…Background Primary analysis from the pivotal ERIVANCE BCC study resulted in approval of vismodegib, a Hedgehog pathway inhibitor indicated for treatment of…”
Get full text

Gene Expression Profiling in BRAF -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib by Wongchenko, Matthew J, McArthur, Grant A, Dréno, Brigitte, Larkin, James, Ascierto, Paolo A, Sosman, Jeffrey, Andries, Luc, Kockx, Mark, Hurst, Stephen D, Caro, Ivor, Rooney, Isabelle, Hegde, Priti S, Molinero, Luciana, Yue, Huibin, Chang, Ilsung, Amler, Lukas, Yan, Yibing, Ribas, Antoni

“…The association of tumor gene expression profiles with progression-free survival (PFS) outcomes in patients with -mutated melanoma treated with vemurafenib or…”
Get full text

42292 Plasma biomarkers for clinical response and disease severity identified from Hidradenitis Suppurativa patients in the phase II AURORA study by Yue, Huibin, Zhao, Niky, Sullivan, Kathleen, Schall, Thomas

Get full text

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial by Brose, Marcia S, Cabanillas, Maria E, Cohen, Ezra E W, Wirth, Lori J, Riehl, Todd, Yue, Huibin, Sherman, Steven I, Sherman, Eric J

“…About half of patients with papillary thyroid cancer have tumours with activating BRAF(V600E) mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor…”
Get full text

767-P: A Phase 1b/2a Study of the Safety and Tolerability of GSBR-1290, a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA), in Healthy Overweight/Obese Volunteers (HOV) and Participants with Type 2 Diabetes Mellitus (T2DM) by Coll, Blai, Zhang, Jinqiang, Chen, Libo, Ibarra, Lani, Yue, Huibin, Barth, Aline, Bach, Mark A

“…Introduction: GSBR-1290 is a novel, oral, non-peptide GLP-1RA and a potential alternative to injectable or oral peptides used for the treatment of T2DM and…”
Get full text

3236 CHANGE IN ALBUMINURIA IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS TREATED WITH AVACOPAN by Geetha, Duvuru, Cortazar, Frank, Karras, Alexandre, Bruchfeld, Annette, Yue, Huibin, Merkel, Peter, Jayne, David

“…Abstract Background and Aims Urinary albumin:creatinine ratio (UACR) is an important biomarker of active glomerulonephritis, a common complication of…”
Get full text

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors by Strickler, John H, Weekes, Colin D, Nemunaitis, John, Ramanathan, Ramesh K, Heist, Rebecca S, Morgensztern, Daniel, Angevin, Eric, Bauer, Todd M, Yue, Huibin, Motwani, Monica, Parikh, Apurvasena, Reilly, Edward B, Afar, Daniel, Naumovski, Louie, Kelly, Karen

“…This first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody-drug conjugate of the anti-c-Met monoclonal…”
Get full text

Effect of Avacopan, a Selective C5a Receptor Inhibitor, on C3G Histologic Index of Disease Chronicity: PO2539 by Bomback, Andrew S., Herlitz, Leal C., Yue, Huibin, Kedia, Priyanka Punit, Schall, Thomas J., Bekker, Pirow

Get full text

Complement C5a Receptor Inhibitor Avacopan Improves Renal Function in ANCA Vasculitis: SU-OR32 by Jayne, David R., Merkel, Peter A., Yue, Huibin, Kelleher, Catherine L., Schall, Thomas J., Bekker, Pirow

Get full text

LB003A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY OF AVACOPAN IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS by Jayne, David, Merkel, Peter, Yue, Huibin, Schall, Thomas J, Kelleher, Catherine, Bekker, Pirow

“…Abstract Background and Aims Complement fragment C5a is strongly linked to the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated…”
Get full text

FC057: Incidence of Infections in the Avacopan Group Versus Prednisone Group in Anca-Associated Vasculitis, Results from the Phase 3 Advocate Study by George, Michael, Kronbichler, Andreas, Pagnoux, Christian, Springer, Jason, W.A. Westman, Kerstin, Yue, Huibin, Bekker, Pirow, Degoma, Emil, Jayne, David, Merkel, Peter

“…Abstract BACKGROUND AND AIMS Standard therapy for ANCA-associated vasculitis (AAV) includes glucocorticoids (GC), which are associated with increased…”
Get full text

Clinical Benefit Assessment of Vismodegib Therapy in Patients With Advanced Basal Cell Carcinoma by Dreno, Brigitte, Basset‐Seguin, Nicole, Caro, Ivor, Yue, Huibin, Schadendorf, Dirk

“…Purpose. Vismodegib was approved for the treatment of advanced basal cell carcinoma (aBCC) based on the pivotal ERIVANCE BCC study. The primary endpoint…”
Get full text

First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors by Demetri, George D, Luke, Jason J, Hollebecque, Antoine, Powderly, 2nd, John D, Spira, Alexander I, Subbiah, Vivek, Naumovski, Louie, Chen, Chris, Fang, Hua, Lai, Dominic W, Yue, Huibin, Polepally, Akshanth R, Purcell, James W, Robinson, Randy, Sharma, Padmanee, Allison, James P, Tolcher, Anthony, Villalobos, Victor M

“…Leucine-rich repeat containing 15 (LRRC15) is expressed on stromal fibroblasts in the tumor microenvironment of multiple solid tumor types and may represent an…”
Get full text

Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors by Tapia, Gonzalo, Lundy, Joanne, Richardson, Gary Edward, Zhao, Niky, Ebsworth, Karen, Yue, Huibin, Miao, Shichang, deGoma, Emil, Jain, Rita, Schall, Thomas J., Sullivan, Kathleen, Zhang, Penglie, de Souza, Paul L.

“…2593 Background: The novel small molecule CCX559 is a highly potent and selective PD-L1 inhibitor that induces the dimerization and internalization of…”
Get full text

Corrigendum to “The Glucocorticoid Toxicity Index: Measuring Change in Glucocorticoid Toxicity Over Time” [Seminars in Arthritis and Rheumatism 55 (2022):152010] by Stone, John H., McDowell, P. Jane, Jayne, David R.W., Merkel, Peter A., Robson, Joanna, Patel, Naomi J., Zhang, Yuqing, Yue, Huibin, Bekker, Pirow, Heaney, Liam G.

Get full text